one of these symptoms, sexual dysfunction (SD), has a striking impact on the lives of patients with MS.
Sexuality is now recognized as one of the major determinants of quality of life in patients with chronic diseases. Sexual satisfaction is considered a relevant variable in assessing social, familial, and affective relations.
Lilius et al. found that SD affects 82%-91% of men and 59%-72% of women with MS compared to 13% in non-MS subjects 1 . Szasz et al. 2 found that 50% of MS patients reported being "concerned" about their sexual life. Lundberg 3 showed that sexual dysfunction is common even in mild and moderate cases. These percentages are extremely important and should be considered by health professionals when providing a multidimensional treatment.
Sexuality is hard to define. Furthermore, it is a private matter that raises many taboos and involves personal, cultural, and religious factors. In order to understand the effects of MS on sexual functioning, it should be noted that the pathways of sexuality control extend through certain brain centers that receive information from the sense organs and limbic regions and send stimuli to medullary centers that control the effector organs of sexual response. The presence of MS lesions can affect points along the sexual response pathway.
Sexual dysfunction in MS is described according to three basic generating factors: 1) primary, a direct result of neurological injuries involving the genital system itself; 2) secondary, a result of symptoms unrelated to the genital system, or 3) tertiary, a result of cultural and psychosocial issues related to the disease that in some way interfere with sexual function 4 . Despite this categorization, it is very common for patients to have more than one type of SD.
The most common primary dysfunctions in MS are reduction or loss of libido, decreased genital sensitivity, pain or a tingling sensation in the genitals, and difficulty in reaching orgasm. Among men, Vas 5 highlights erectile dysfunction, which affects between 60% and 80% of patients.
The secondary dysfunctions include spasticity (especially in the lower extremities), fatigue, muscle weakness, urinary and/or fecal incontinence, pain and paresthesia, tremor, shuddering, impaired attention and concentration, and behavioral changes.
Tertiary dysfunctions are mainly related to the social impact of the disease on self-esteem, mood, and personal and professional life. Considering all the above-mentioned factors, it is important to develop an effective survey strategy to elucidate and measure the main impacting features of SD. In a review of sexual function in MS patients, Dupont 6 determined that one of the biases in studies of sexuality is the limited use of standardized instruments.
The Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (MSISQ-19), a scale that assesses SD considering the three levels of compromise, was empirically developed as a specific scale to address the multidimensional nature of sexual issues in MS 7 . The MSISQ-19 was previously used as a tool to evaluate SD in MS 8 ; Foley has recently developed and validated a version with 15 items of the scale based on a large sample of North American patients 9 .
The questionnaire is self-completed and there is a risk that it might be interpreted differently across cultures and populations. Thus, it is recommended that these questionnaires be pre-tested and validated for each population. In this context, the aim of the present study was to adapt and validate the MSISQ-19 to be used as an assessment tool of the impact of sexual dysfunction on Brazilian patients with MS while maintaining the core characteristics of the original version.
The aim of this study was to develop a cross-cultural adaptation and validation of the MSISQ-19 so that it can be used as a tool to evaluate SD in Brazilian patients with MS.
metHoD

Instrument
The MSISQ -19 is composed of 19 self-report items measuring the influence of MS symptoms on sexual activity and satisfaction and how they have interfered with the patient's sexual life over the preceding six months. The instrument is divided into three subscales: SD1, for primary sexual dysfunction (items 12, 16, 17, 18, and 19); SD2, secondary (items 1, 2, 3, 4, 5, 6, 8, 10, and 11), and SD3, tertiary (items 7, 9, 13, 14, and 15). Each item is rated from 1-5 based on the Likert scale (1 = never; 2 = seldom; 3 = sometimes; 4 = often, and 5 = always); a final score is generated by the summation of the scores across items. The higher the score, the greater the impact of SD on patients' lives 10 . The Expanded Disability Status Scale (EDSS) is a 10-point scale typically employed to assess the progression of MS-related disability. The scale has 20 levels of clinical impairment graded in 0.5 increments, with 0 (zero) being the best score (normal neurological examination) and 10 the worst (death from MS) 11 .
translation and cultural adaptation
The cross-cultural adaptation and validation protocols were followed according to specialized literature 12 .
Initially, the items of the English version were translated into Portuguese by two independent English teachers who were aware of the objective of the study. These two translations were compared and modifications were made until consensus was reached. The consensus translation was back-translated into English by a native English teacher who had not participated in the previous step. The back-translated English version and the original questionnaires were compared and no significant discrepancies were noted.
A pilot study was carried out for pre-test analysis of cultural equivalence. The scale was applied to a group of 11 MS patients without cognitive impairment selected randomly at the Centre of Care and Treatment of Multiple Sclerosis (CATEM) at the Santa Casa de Misericórdia de São Paulo. The purpose of this procedure was to identify issues that were not understood by the population and therefore were deemed culturally inappropriate; however, no question fit those parameters. Thus, the final versions of the Portuguese language scale, named MSISQ-19-BR, were generated.
subjects
In all, 134 patients with MS, including 99 women and 35 men, were selected. The control group comprised 70 non-MS subjects, with 46 females and 24 males. The patients with MS were randomly selected among those being treated at the CATEM.
The inclusion criteria was a confirmed diagnosis of MS according to the revised McDonald criteria 2010 and the absence of other pathological conditions that might lead to SD, such as psychological disorders, abnormal hormonal activity, vaginismus, previous erectile dysfunction, sexual arousal disorders and use of specific medication, among others. Participants were excluded if they were undergoing an MS outbreak. All subtypes of MS were included, trying to respect the prevalence proportion. The 70 non-MS subjects were randomly selected among accompanying of patients with MS at the CATEM and of other patients with other conditions being treated at the same hospital. The exclusion criteria for the control group were having MS or any other pathology that might cause SD.
All subjects were informed about the purpose of the study and provided written informed consent.
The MSISQ-19 questionnaire was administered in a quiet and private environment to minimize possible constraints. Data regarding gender, age, level of education, disease duration and MS subtype, neurological examination, and EDSS score were collected. After 30 days, the same researchers gave a retest with 48 patients to analyze the stability and reliability of the scale.
statistical analysis
Descriptive analysis was done based on the frequency of categorical variables and measures of position and dispersion of continuous variables. A multivariate analysis of variance was performed for gender, age, level of education, disease duration, and EDSS score to identify extraneous variables. The results were analyzed and compared between the control group and patients with MS in order to clarify the significance of the final score.
To validate the instrument, we followed the standards proposed by Instrument Review Criteria (SAC) and assessed reliability, validity, and sensitivity 13, 14 . The reliability of the questionnaire was assessed based on internal consistency and test-retest stability, obtained respectively by Cronbach's alpha and Pearson's correlation coefficients. The validity of the instrument was determined by comparing the results of the MSISQ-19-BR with the EDSS scores using Pearson's correlation coefficient. The sensitivity of the scale was established by comparing the results of four different groups: control group with and without SD; MS patients with and without SD. This subdivision allowed an evaluation of the ability of the scale to identify each of these four groups using the Mann-Whitney and Kruskal-Wallis tests Table 1 . The multivariate analysis of variance showed that gender, age, and level of education did not affect the results of the test and retest nor the subsequent analysis.
Among the patients with MS, 54.3% of the male individuals and 71.7% of the female exhibited some degree of SD, defined as a score greater than 30 or any response 4 (often) or 5 (always). For the control group, the results were 12.5% and 19.5%, respectively. The means and standard deviations for the SD1, SD2 and SD3 subscales and the total score of the MS group were compared between male and female subjects ( Table 2) .
The internal consistency for the subscales (SD1, SD2 and SD3) and between the 19 questions in MSISQ-19-BR was assessed using Cronbach's alpha coefficient for all subjects and individually for each group. These results are shown in Table 3 .
A high level of reproducibility was found, with 86.76% of concordance between the studied behaviors. The 16 , no significant correlations were observed in our study, which is consistent with the results of the study by Tzortzis et al. 17 . Sensitivity is a measure of the ability of a scale to distinguish groups with different characteristics. The study subjects were divided into four groups (control and MS, with or without SD) and the scores were compared using the Mann-Whitney and Kruskal-Wallis tests. The results are shown in Tables 4 and 5 .
DIscussIoN
Sexual satisfaction is considered a relevant variable in quality of life assessments. Problems with sexual function are common in patients suffering from degenerative and disabling diseases.
Zorzon et al. 18 reported that the incidence of SD in patients with MS (73%) is higher than in people with chronic diseases (39%) and in the general population (13%). The incidence of SD in our study was approximately 72% in women and 54% in men. Other studies have found incidence rates ranging from 50% to more than 70%. In a study by Lilius et al. 1 , 64% of men and 39% of women described their sex life as "unsatisfactory". Sexual dysfunction seems to be affected by the level of disability and disease duration, but the impact of those factors remains unclear. Hulter and Lundberg noted that 90% of MS patients using wheelchairs have "big problems with sexual function" 19 , which need to be properly addressed.
Patients with MS have high levels of SD and their partners also show less satisfaction with their sex lives and relationships. How patients react to the perception of their disease by others impacts their sexual behavior.
If the patient with MS becomes unable to engage in sexual activity, the partner and the whole family dynamics can be affected. Sexual satisfaction is frequently associated with acceptance, trust, and communication. Therefore, SD should not be treated as a single somatic disorder; rather, it should also be seen in its cognitive and emotional aspects, thus helping patients to find a new path in their sex lives.
Most researchers suggest that MS has a negative impact on relationships and satisfaction with the romantic relationship is lower than in the general population 20, 21, 22 . Health professionals should be aware of the high rates of SD and low levels of sexual satisfaction among individuals with MS. Nevertheless, it is estimated that 94% of MS patients have never been questioned about their sexuality 21 . Disorders related to sexuality are often pushed into low priority by health professionals, especially because of the difficulties in effectively approaching this subject and the lack of more specialized information. Patients often feel uncomfortable and unable to speak about their sexuality, but most of them believe it to be appropriate to address sexual functioning in routine office visits 23 . Previous studies have demonstrated that sexual counseling is helpful 24 ; educational materials and conversations about sexual problems in MS also seemed beneficial 25 . In providing care, it is important for the health professional to find a balance between distance and intimacy, allowing patients to address their sexual issues without judgment. First of all, the physician should perform a complete evaluation and determine what type of SD the patient manifests and whether it appeared before or after the onset of MS symptoms.
Treatment of any SD begins with information provided to patients; however, other factors should be considered, such as the etiology of the disorder, the patient's age, sexual experience, and whether the patient and partner are in a steady relationship. Bronner et al. 26 suggested some interventions that could minimize the impact of SD: hormone administration, treatment of underlying conditions (e.g., depression, urinary incontinence), and masturbation, among others.
Therapy starts when the physician shows concern about the patient's sex life. It is important to consider that, despite the high prevalence of SD in MS, other conditions should not be neglected, such as hypertension, diabetes, incontinence, psychiatric disorders, and side effects of drugs 27 . Assessing the prevalence and cause of sexual problems that may require clinical intervention is essential.
Depression, for example, is highly prevalent in MS patients 28, 29 . The feeling of dependence related to depressive episodes can also cause decreased sexual drive. The fear of being rejected sexually, the feeling of being less attractive, communication difficulties, fear of isolation and abandonment, guilt, and the impact of the disease on the partner-especially when he or she becomes the caregiver-are some of the prominent issues.
In this context, some areas related to sexual behavior should be explored: responsiveness to sexual stimulation, motor difficulties, hygiene aspects, urinary and fecal incontinence, fertility, libido, communication with partners, and prospects for sex life. Considering all the aspects that have been discussed, the present study confirms the need to address sexuality in MS patients. The use of a standardized tool can facilitate the initial approach and introduce the topic in a non-threatening way in clinical practice.
In conclusion, the MSISQ-19-BR is a reproducible, reliable, and valid instrument for the Brazilian population. It also showed easy clinical applicability and can be used in the day-to-day care of patients with MS. The administration of a standardized instrument can facilitate the initial approach and introduce the theme of sexuality in regular physician office visits. Therefore, the MSISQ-19-BR is a valuable tool to help physicians and patients in addressing this sensitive subject and to enable a multidimensional treatment, thereby improving the quality of life of MS patients. 
